Cara Therapeutics, Inc.
4 Stamford Plaza 107 Elm Street, 9th floor
Stamford
Connecticut
06902
United States
Tel: 203-567-1500
Fax: 203-567-1510
Website: http://www.caratherapeutics.com/
Email: info@caratherapeutics.com
245 articles about Cara Therapeutics, Inc.
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2020.
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
2/18/2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021, at 4:30 p.m. E
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news. -
Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia ParestheticaExpands clinical development of Oral KORSUVA™ into neuropathic pruritus
1/11/2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA™
-
Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. ET.
-
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
12/28/2020
First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection
-
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics
12/24/2020
Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October
-
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
12/2/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has completed full enrollment of its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA™ (difelikefalin tablets) for the treatment o
-
Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
11/11/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in the following upcoming virtual investor conferences and events in November and December: Stifel 2020 V
-
Cara Therapeutics Reports Third Quarter 2020 Financial Results
11/9/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2020.
-
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
11/2/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 9, 2020, at 4:30 p.m. ET to report third quarter 2020 financial results and provide a corporate update.
-
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics
10/27/2020
First of multiple anticipated milestone payments related to the development of Oral KORSUVA™
-
Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020
10/21/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that results from its KALM-2 pivotal Phase 3 trial of KORSUVA
-
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
10/20/2020
Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.
-
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
10/20/2020
Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.
-
Under terms of the Korsuva deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.
-
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
10/1/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020.
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
8/10/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced financial results and operational highlights for the second quarter ended June 30, 2020.
-
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
8/6/2020
Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:00 a.m. ET.
-
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
8/3/2020
Cara Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020, at 4:30 p.m. ET to report second quarter 2020 financial results and provide a corporate update.